Kiniksa Pharmaceuticals International, plc (KNSA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q2 '21: 7.7M Q3 '21: 12.1M Q4 '21: 18.7M Q1 '22: 32.2M Q2 '22: 27M Q3 '22: 99.1M Q4 '22: 61.9M Q1 '23: 48.3M Q2 '23: 71.5M Q3 '23: 67M Q4 '23: 83.4M Q1 '24: 79.9M Q2 '24: 108.6M Q3 '24: 112.2M Q4 '24: 122.5M Q1 '25: 137.8M Q2 '25: 156.8M Q3 '25: 180.9M Q4 '25: 202.1M Q1 '26: 214.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit Quarterly

0 70M 140M 210M Q2 '21: 5.2M Q3 '21: 9.3M Q4 '21: 14.9M Q1 '22: 28M Q2 '22: 21.9M Q3 '22: 92.2M Q4 '22: 55.2M Q1 '23: 41.3M Q2 '23: 63.8M Q3 '23: 58M Q4 '23: 73.8M Q1 '24: 69.3M Q2 '24: 96.3M Q3 '24: 92.1M Q4 '24: 104.6M Q1 '25: 119.9M Q2 '25: 138.2M Q3 '25: 160.6M Q4 '25: 181.2M Q1 '26: 193.5M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q2 '21: -40.6M Q3 '21: -30.7M Q4 '21: -36.1M Q1 '22: -23.3M Q2 '22: -19.4M Q3 '22: 46.4M Q4 '22: 6M Q1 '23: -11.2M Q2 '23: -3.2M Q3 '23: -10.9M Q4 '23: 81K Q1 '24: -16.5M Q2 '24: -117K Q3 '24: -9.7M Q4 '24: -19.3M Q1 '25: 13.3M Q2 '25: 20.2M Q3 '25: 24M Q4 '25: 19.8M Q1 '26: 29.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income Quarterly

-80M 0 80M 160M 240M Q2 '21: -41.6M Q3 '21: -30.5M Q4 '21: -36.3M Q1 '22: -25.2M Q2 '22: -20M Q3 '22: 224.1M Q4 '22: 4.5M Q1 '23: -12.3M Q2 '23: 15M Q3 '23: -13.9M Q4 '23: 25.2M Q1 '24: -17.7M Q2 '24: -3.9M Q3 '24: -12.7M Q4 '24: -8.9M Q1 '25: 8.5M Q2 '25: 17.8M Q3 '25: 18.4M Q4 '25: 14.2M Q1 '26: 22.6M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue Quarterly

0 8M 16M 24M Q2 '21: 2.5M Q3 '21: 2.8M Q4 '21: 3.9M Q1 '22: 4.2M Q2 '22: 5M Q3 '22: 6.9M Q4 '22: 6.7M Q1 '23: 7M Q2 '23: 7.7M Q3 '23: 9.1M Q4 '23: 9.6M Q1 '24: 10.6M Q2 '24: 12.3M Q3 '24: 20.1M Q4 '24: 17.9M Q1 '25: 17.9M Q2 '25: 18.6M Q3 '25: 20.3M Q4 '25: 20.9M Q1 '26: 20.8M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating Cash Flow Quarterly

-50M -25M 0 25M 50M 75M Q2 '21: -38.8M Q3 '21: -28.5M Q4 '21: -18.9M Q1 '22: -36.8M Q2 '22: -7.8M Q3 '22: 62.1M Q4 '22: -11.6M Q1 '23: -4.3M Q2 '23: -3.7M Q3 '23: 17M Q4 '23: 4.3M Q1 '24: 4M Q2 '24: 5.2M Q3 '24: -2.2M Q4 '24: 18.8M Q1 '25: 22.3M Q2 '25: 28.1M Q3 '25: 33.7M Q4 '25: 53.9M Q1 '26: 50.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow Quarterly

-50M -25M 0 25M 50M 75M Q3 '20: -34.3M Q4 '20: -41.2M Q1 '21: -40.2M Q2 '21: -38.8M Q3 '21: -28.6M Q4 '21: -19.1M Q3 '22: 62M Q1 '23: -4.3M Q2 '23: -3.8M Q3 '23: 17M Q4 '23: 4.3M Q1 '24: 3.9M Q2 '24: 5.2M Q3 '24: -2.2M Q4 '24: 18.6M Q1 '25: 22.2M Q2 '25: 27.9M Q3 '25: 33M Q4 '25: 53.3M Q1 '26: 50M Q4 '20 Q3 '21 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '21: 68.3M Q2 '21: 68.4M Q3 '21: 68.7M Q1 '22: 69.1M Q2 '22: 69.3M Q3 '22: 70.6M Q1 '23: 69.8M Q2 '23: 71.6M Q3 '23: 70.2M Q1 '24: 70.6M Q2 '24: 71M Q3 '24: 71.7M Q1 '25: 76.1M Q2 '25: 77.9M Q3 '25: 80M Q1 '26: 82.4M Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q2 '21: -2.80 Q3 '21: -2.58 Q4 '21: -2.29 Q1 '22: -1.93 Q2 '22: -1.61 Q3 '22: 2.01 Q4 '22: 2.58 Q1 '23: 2.76 Q2 '23: 3.26 Q3 '23: -0.12 Q4 '23: 0.19 Q1 '24: 0.12 Q2 '24: -0.15 Q3 '24: -0.13 Q4 '24: -0.61 Q1 '25: -0.25 Q2 '25: 0.04 Q3 '25: 0.45 Q4 '25: 0.75 Q1 '26: 0.91 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.